Clinical and Laboratory Profile of the 12 Myeloma Patients
| Patient . | Age/Sex . | Dx . | Ig . | Pcytoma . | Histology . | Stage . | R (f) . | Alb . | % BMPC . | P16 . | P15 . | Tx . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 52 M | BILPs | Gλ | − | Mature | III | N | Low | 90 | M | M | MP |
| 2* | 63 M | BILps | Dλ | − | Blastic | III | I | Low | 100 | M | M | VAD → MP |
| 3 | 42 F | BILPs | Gλ | + | Intermediate | III | N | Low | 80 | M | M | CEVAD‡ |
| 4 | 48 M | BILPs | Gλ | − | Mature | III | N | Low | 80 | N | N | MP |
| 5 | 38 M | bILPu | K | + | Monocytoid | I | N | Low | 25 | M | M | RT → CEVAD |
| 6 | 47 M | BILps | Aλ | − | Blastic† | III | N | Low | 50 | M | M | CEVAD‡ |
| 7 | 59 M | BILPs | Gλ | − | Mature | III | N | Low | 40 | N | N | MP |
| 8 | 80 F | BILps | GK | − | Mature | III | I | Low | 90 | M | M | RT + D |
| 9 | 41 F | BIPs | GK | − | Intermediate | II | N | Low | 35 | N | N | CEVAD‡ |
| 10 | 68 M | BILps | Aλ | − | Blastic | III | N | N | 52 | M | N | MP |
| 11 | 61 M | BILPu | K | + | Blastic | II | I | N | 90 | M | M | MP + RT‡ |
| 12 | 66 F | BIPs | AK | − | Mature | III | I | Low | 32 | M | M | M ± P |
| Patient . | Age/Sex . | Dx . | Ig . | Pcytoma . | Histology . | Stage . | R (f) . | Alb . | % BMPC . | P16 . | P15 . | Tx . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 52 M | BILPs | Gλ | − | Mature | III | N | Low | 90 | M | M | MP |
| 2* | 63 M | BILps | Dλ | − | Blastic | III | I | Low | 100 | M | M | VAD → MP |
| 3 | 42 F | BILPs | Gλ | + | Intermediate | III | N | Low | 80 | M | M | CEVAD‡ |
| 4 | 48 M | BILPs | Gλ | − | Mature | III | N | Low | 80 | N | N | MP |
| 5 | 38 M | bILPu | K | + | Monocytoid | I | N | Low | 25 | M | M | RT → CEVAD |
| 6 | 47 M | BILps | Aλ | − | Blastic† | III | N | Low | 50 | M | M | CEVAD‡ |
| 7 | 59 M | BILPs | Gλ | − | Mature | III | N | Low | 40 | N | N | MP |
| 8 | 80 F | BILps | GK | − | Mature | III | I | Low | 90 | M | M | RT + D |
| 9 | 41 F | BIPs | GK | − | Intermediate | II | N | Low | 35 | N | N | CEVAD‡ |
| 10 | 68 M | BILps | Aλ | − | Blastic | III | N | N | 52 | M | N | MP |
| 11 | 61 M | BILPu | K | + | Blastic | II | I | N | 90 | M | M | MP + RT‡ |
| 12 | 66 F | BIPs | AK | − | Mature | III | I | Low | 32 | M | M | M ± P |
Abbreviations: Dx, diagnosis; B, myeloma cell infiltration >30% of total nucleated cells (TNC) in BM; b, myeloma cell infiltration >10%, <30% of TNC in BM; I, immunoparesis, normal IgM <50 mg %, IgA <80 mg %, IgG <600 mg %; L, osteolytic lesions; P, major paraprotein level (fulfil major criteria of Durie & Salmon); s, serum; u, urine; p, minor paraprotein level (fulfil minor criteria of Durie & Salmon); Ig, immunoglobulin isotype; Pcytoma, plasmacytoma; R (f), renal function; N, normal; I, impaired; Alb, albumin; % BMPC, % BM plasma cells; P16, P15, M, methylation; Tx, treatment; M, melphalan; P, prednisolone; V, vincristine; A, adriamycin; D, dexamethasone; C, cyclophosphamide; E, etoposide; RT, radiotherapy.
Died shortly.
Anaplastic morphology.
Posttreated.